Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

RaKa82 Dec. 10 at 8:17 PM

$IMNN 3x the average daily trading volume today. Interesting

0 · Reply

rrch Dec. 10 at 7:09 PM

$IMNN I am thinking that they deliver here on a major Asia partner

1 · Reply

rrch Dec. 10 at 7:05 PM

$IMNN after the close

0 · Reply

ConcernedCitizen23 Dec. 10 at 6:52 PM

$IMNN just to remind people…this company has started phase 3 with multiple patients enrolled at 4 centers with plans reported by ceo to increase to 8 centers. Each woman with ovarian cancer gets $20,000-50,000 chemo…20,000 each year in US and 90,000 across the world. Thats $4.5billion/year income at top end/max. Market cap $12MILLION

1 · Reply

tommy_john Dec. 10 at 5:29 PM

$IMNN anyone here?

1 · Reply

bomber1 Dec. 10 at 8:34 AM

$IMNN America conducts research with investors' money!!! This is the truth!!! I think Imunon is not the only publicly traded biotech company that raises funds with shareholder contributions!! But here there is the approval of the American governments that do not put a stop to this phenomenon!! Many countries in the world do not conduct research, but neither do they steal money from savers!!! This is where the difference in honesty of behavior and political coherence lies!!!! The dilution of capital is simply a clever scam, or rather, a robbery to the detriment of ordinary people!!!

1 · Reply

LKDOG Dec. 10 at 12:35 AM

$IMNN https://www.ddw-online.com/the-potential-of-dna-platforms-for-infectious-disease-vaccines-38265-202510/

0 · Reply

LKDOG Dec. 10 at 12:31 AM

$IMNN

0 · Reply

jjegglie Dec. 9 at 8:38 PM

$IMNN They just put a new fake medicine into a 7 year trial. They will continue the dilute/reverse split cycle another 6.5 years on that grift. Down 99.99999% from all time high, currently bumping along just above all time lows

0 · Reply

LKDOG Dec. 9 at 7:58 PM

$IMNN Imagine a marketing program during the holidays . “ Lilly wishes all women Happy holidays &and ; a cancer free new year “ !

0 · Reply

Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:45 AM EST - 4 weeks ago

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 5:11 PM EST - 4 weeks ago

Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript

Nov 10, 2025, 1:30 PM EST - 4 weeks ago

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Nov 10, 2025, 7:30 AM EST - 4 weeks ago

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Nov 7, 2025, 8:05 AM EST - 4 weeks ago

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Nov 6, 2025, 8:05 AM EST - 5 weeks ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Nov 4, 2025, 8:05 AM EST - 5 weeks ago

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 30, 2025, 8:00 AM EDT - 6 weeks ago

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

Oct 23, 2025, 10:01 AM EDT - 6 weeks ago

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Oct 20, 2025, 8:05 AM EDT - 7 weeks ago

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 17, 2025, 8:10 AM EDT - 7 weeks ago

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

Oct 14, 2025, 8:20 AM EDT - 2 months ago

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Sep 22, 2025, 8:05 AM EDT - 2 months ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Sep 19, 2025, 8:05 AM EDT - 2 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

Aug 28, 2025, 8:05 AM EDT - 3 months ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 4 months ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 1:26 PM EDT - 4 months ago

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 4 months ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 4 months ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 5 months ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 5 months ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 6 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 6 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 6 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 6 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 7 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 7 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 7 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 7 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 7 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 12:56 PM EDT - 7 months ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:00 AM EDT - 7 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 7 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 7 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 7 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 9 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 2:32 PM EST - 10 months ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 8:05 AM EST - 10 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 10 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 10 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 10 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 10 months ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 10, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Nov 25, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Nov 7, 2024, 5:11 PM EST - 1 year ago

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

RaKa82 Dec. 10 at 8:17 PM

$IMNN 3x the average daily trading volume today. Interesting

0 · Reply

rrch Dec. 10 at 7:09 PM

$IMNN I am thinking that they deliver here on a major Asia partner

1 · Reply

rrch Dec. 10 at 7:05 PM

$IMNN after the close

0 · Reply

ConcernedCitizen23 Dec. 10 at 6:52 PM

1 · Reply

tommy_john Dec. 10 at 5:29 PM

$IMNN anyone here?

1 · Reply

bomber1 Dec. 10 at 8:34 AM

1 · Reply

LKDOG Dec. 10 at 12:35 AM

$IMNN https://www.ddw-online.com/the-potential-of-dna-platforms-for-infectious-disease-vaccines-38265-202510/

0 · Reply

LKDOG Dec. 10 at 12:31 AM

$IMNN

0 · Reply

jjegglie Dec. 9 at 8:38 PM

0 · Reply

LKDOG Dec. 9 at 7:58 PM

$IMNN Imagine a marketing program during the holidays . “ Lilly wishes all women Happy holidays &and ; a cancer free new year “ !

0 · Reply

bobbythek Dec. 9 at 7:51 PM

$IMNN OMG! This company still around!!! How many reverse splits in last 15 years? Think down about 97% over that period...Sham.

0 · Reply

RaKa82 Dec. 9 at 5:00 PM

$IMNN were effectively a rounding error for Lilly’s glp $. A highly undervalued Ph3 asset like ours is right up Lilly’s alley https://endpoints.news/eli-lilly-will-be-aggressive-in-spending-glp-1-money-says-top-dealmaker-van-naarden/

2 · Reply

LKDOG Dec. 9 at 4:47 PM

$IMNN Can a brother get a buy out ?!!!! 😎

1 · Reply

ConcernedCitizen23 Dec. 8 at 5:40 PM

$IMNN this stock is so ridiculously cheap right now that any country in the world can buy it, use the tech and get it through the regulatory process for pennies on the dollar compared to paying big pharma for this later $20,000-50,000 per treatment course x thousands of patients per year in each country. They can save billions for their national health insurance programs.

2 · Reply

rrch Dec. 8 at 4:05 PM

$IMNN I think an international partner is going to happen soon maybe some nice non diluted money

1 · Reply

Ferryf Dec. 8 at 11:56 AM

$IMNN If license outside US is going to be like $SMX Low floater

0 · Reply

LKDOG Dec. 7 at 3:48 PM

$IMNN While Market beat shows $200 plus related to Defeating ovarian Cancer, keep in mind the DNA vaccines are just getting traction. MRNA vaccines will be displaced by DNA alternatives by IMMN, due to MAJOR cardiovascular issues & deaths. Could be wrong, but I don’t believe the valuation of IMNN future DNA vaccines has been considered as part of Market beats valuation of IMNN. I’m sure it is tool early .

1 · Reply

LKDOG Dec. 6 at 4:17 PM

$IMNN

1 · Reply

RaKa82 Dec. 5 at 8:31 PM

$IMNN

0 · Reply

RaKa82 Dec. 5 at 3:39 PM

$IMNN does anyone know if they’ve said anything about JPM in January? Are they attending?

1 · Reply

ConcernedCitizen23 Dec. 4 at 10:49 PM

$IMNN available short shares

1 · Reply

Ioseba Dec. 4 at 10:16 PM

$IMNN tock tock tick tock....

1 · Reply

Market Cap	12.19M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	118,200
Avg Vol	63,438
Day's Range	N/A - N/A
Shares Out	3.07M
Stochastic %K	67%
Beta	1.94
Analysts	Strong Sell
Price Target	$25.09